High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: Case report and review of the literature

Brachytherapy

Volumn 12, Issue 1, 2013, Pages 77-83

  Nguyen, Paul L ^a   Devlin, Phillip M ^a   Beard, Clair J ^a   Orio, Peter F ^a   O'Leary, Michael P ^a   Wolfsberger, Luciant D ^a   O'Farrell, Desmond A ^a   Sweeney, Christopher M ^a   Hadaschik, Boris A ^b   Hohenfellner, Markus ^b   Hatiboglu, Gencay ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Hydrogel; Prostate cancer; Salvage radiotherapy; Spacer

Indexed keywords

ANTIANDROGEN; CAPECITABINE; MACROGOL; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; DIGITAL RECTAL EXAMINATION; DOSIMETRY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME; URETHRA;

BRACHYTHERAPY; HUMANS; HYDROGELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION PROTECTION; RECTUM; TREATMENT OUTCOME;

EID: 84871793014     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2012.03.005     Document Type: Article

References (35)

1. Lee B., Shinohara K., Weinberg V., et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007, 67:1106-1112.
2. Jabbari S., Hsu I.C., Kawakami J., et al. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy 2009, 8:339-344.
3. Nguyen P.L., D'Amico A.V., Lee A.K., et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: A systematic review of the literature. Cancer 2007, 110:1417-1428.
4. Garzotto M., Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: Results at 5-year followup. J Urol 1998, 159:950-954. discussion 4-5.
5. Stephenson A.J., Scardino P.T., Bianco F.J., et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004, 172:2239-2243.
6. Bales G.T., Williams M.J., Sinner M., et al. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology 1995, 46:676-680.
7. Long J.P., Fallick M.L., LaRock D.R., et al. Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma. J Urol 1998, 159:477-484.
8. Izawa J.I., Madsen L.T., Scott S.M., et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: Variables affecting patient outcome. J Clin Oncol 2002, 20:2664-2671.
9. Perrotte P., Litwin M.S., McGuire E.J., et al. Quality of life after salvage cryotherapy: The impact of treatment parameters. J Urol 1999, 162:398-402.
10. Pisters L.L., Perrotte P., Scott S.M., et al. Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 1999, 17:2514-2520.
11. Beyer D.C. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999, 54:880-883.
12. Nguyen P.L., Chen M.H., D'Amico A.V., et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: A prospective phase 2 study. Cancer 2007, 110:1485-1492.
13. Wong W.W., Buskirk S.J., Schild S.E., et al. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 2006, 176:2020-2024.
14. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 2009, 373:301-308.
15. Warde P.R., Mason M.D., Ding K., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomized, phase 3 trial. Lancet 2011, 378. 2104-2011.
16. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
17. Wang J.Z., Li X.A., Yu C.X., et al. The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys 2003, 57:1101-1108.
18. Miralbell R., Roberts S.A., Zubizarreta E., et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: Alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012, 82:e17-e24.
19. Leborgne F., Fowler J., Leborgne J.H., et al. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 68:746-750.
20. Martinez A.A., Pataki I., Edmundson G., et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys 2001, 49:61-69.
21. Martin T., Baltas D., Kurek R., et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 2004, 180:225-232.
22. Corner C., Rojas A.M., Bryant L., et al. A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:441-446.
23. Yoshioka Y., Konishi K., Sumida I., et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2010, 80:469-475.
24. Mark R.J., Anderson P.J., Akins R.S., et al. Interstitial high dose rate (HDR) brachytherapy as monotherapy for early stage prostate cancer: Median 8 year results in 312 patients. Int J Radiat Oncol Biol Phys 2010, 78:S147.
25. Phan J., Swanson D.A., Levy L.B., et al. Late rectal complications after prostate brachytherapy for localized prostate cancer: Incidence and management. Cancer 2009, 115:1827-1839.
26. Prada P.J., Fernandez J., Martinez A.A., et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:95-102.
27. Prada P.J., Gonzalez H., Menendez C., et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009, 8:210-217.
28. Wilder R.B., Barme G.A., Gilbert R.F., et al. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:824-830.
29. Wilder R.B., Barme G.A., Gilbert R.F., et al. Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy. Brachytherapy 2010, 10:44-50.
30. Noyes W.R., Hosford C.C., Schultz S.E. Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 2012, 82:1918-1922.
31. Daar E., King L., Nisbet A., et al. Viscosity changes in hyaluronic acid: Irradiation and rheological studies. Appl Radiat Isot 2010, 68:746-750.
32. Tokita K.M., Chittenden L., Mesa A., et al. The use of an injectable spacer material in conjunction with high dose-rate brachytherapy for prostate cancer. Brachytherapy 2011, 10:S51.
33. Harrison JA, Chittenden K, Mesa A, et al. The use of an injectable tissue spacer in conjunction with adaptive radiotherapy for prostate cancer [Abstract]. Paper presented at Cancer Imaging and Radiation Therapy Symposium; 2011 April 29-30; Atlanta, GA.
34. Susil R.C., McNutt T.R., DeWeese T.L., et al. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:1251-1258.
35. Pinkawa M., Djukic V., Holy R., et al. Application of a spacer between prostate and anterior rectal wall to optimize radiotherapy of localized prostate cancer. Strahlenther Onkol 2011, 187:42-43.